Vai alla homepage

Pagina 2 - I migliori medici di Chemioterapia per carcinoma mammario - TOP-80medici

Il contenuto è conforme alla Politica editoriale di Bookimed ed è revisionato da medici

Fahad Mawlood

Viola Fox

  • 4.7 Eccellente 65 recensioni
  • 14 anni di esperienza
  • Germania, Solingen, Medical Center in Solingen
  • Specializzato in chemioterapia, immunoterapia e terapia mirata per il cancro al seno presso il Medical Center di Solingen.

    • Oltre 15 anni di esperienza in ematologia e oncologia
    • Primario presso un centro oncologico interdisciplinare certificato
    • Esperto in diagnostica molecolare e trattamenti innovativi
    • Membro di società oncologiche tedesche e americane
    • Specialista qualificato in genetica per terapie personalizzate
  • Mostra di più
Informazioni

Elke Jaeger

  • 4.5 Buono 57 recensioni
  • 41 anni di esperienza
  • Germania, Francoforte sul Meno, Nordwest Clinic (Krankenhaus)
  • La Prof.ssa Elke Jaeger è riconosciuta come uno dei principali oncologi della Germania secondo la classifica di Focus, con oltre 35 anni di esperienza.

    • Responsabile di Oncologia ed Ematologia presso la Nordwest Klinik
    • Specializzata in sarcoma – un tipo di cancro raro e complesso
    • Vasta esperienza nei protocolli di chemioterapia
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Séverine Iborra

  • 4.7 Eccellente 65 recensioni
  • 19 anni di esperienza
  • Germania, Solingen, Medical Center in Solingen
  • La Dott.ssa Séverine Iborra dirige la Clinica di Senologia presso il Centro Senologico di Solingen, specializzandosi nella cura del cancro al seno.

    • Medico Primario di Ginecologia e Ostetricia presso lo Städtisches Klinikum di Solingen
    • Specializzata in Oncologia Ginecologica con qualifiche aggiuntive in diagnostica oncologica
    • Membro attivo delle principali società mediche tedesche in ginecologia e ostetricia
    • Esperta in trattamenti minimamente invasivi, inclusi la laparoscopia e la chirurgia robotica
    • Autrice di numerose pubblicazioni e relatrice in importanti conferenze ginecologiche
  • Mostra di più
Informazioni

Ozcan Yildiz

  • 4.5 Buono 495 recensioni
  • 76 anni di esperienza
  • Turchia, Istanbul, Medipol Mega University Hospital
  • Dr. Yildiz has published numerous articles in international peer-reviewed journals, examining topics such as Gastroenteropancreatic neuroendocrine tumors, lipid-lowering treatment, dexamethasone suppression tests, thyroxin therapy, familial Mediterranean fever, and idiopathic thrombocytopenia. These articles have been published in journals such as Medical Oncology, J Endocrinol Invest, Swiss Med Wkly, Int J Cardiol, Eur J Med Res, Ethiop Med J, Gynecol Oncol, Med Hypotheses, Int J Gynecol Cancer, Med Oncol, West Indian Med J, and Cases J.
  • Mostra di più
Informazioni

Irina Stepfansky

  • 4.5 Buono 165 recensioni
  • 26 anni di esperienza
  • Israele, Tel Aviv-Giaffa, Sourasky Medical Center (Ichilov)
  • Il dottore si è laureato all'Università di Grodno, Bielorussia, e ha ottenuto la licenza medica in Israele nel 2000. Specializzandosi in medicina interna e oncologia, il dottore ha completato tirocini nel 10° Dipartimento di Medicina Interna e Oncologia presso il Centro Medico di Tel Aviv, Ichilov. Dal 2015, il dottore è direttore del reparto di ospedalizzazione oncologica nello stesso centro.<\/p>

    Con una vasta esperienza come ricercatore primario e secondario, il dottore ha partecipato a studi clinici di prima, seconda e terza fase in oncologia, contribuendo significativamente al campo.<\/p>

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Fredi Aviv

  • 4.5 Buono 165 recensioni
  • 34 anni di esperienza
  • Israele, Tel Aviv-Giaffa, Sourasky Medical Center (Ichilov)
  • Il medico è un oncoematologo esperto con 31 anni di pratica presso il Sourasky Medical Center. Specializzandosi nel trattamento dei tumori del sangue, il medico ha contribuito significativamente ai progressi in oncoematologia. Con un focus sulla cura centrata sul paziente, il medico ha partecipato a numerosi studi clinici e progetti di ricerca volti a migliorare i risultati terapeutici. Il medico è riconosciuto per la sua esperienza nella diagnosi e gestione di condizioni ematologiche complesse, fornendo cure complete ai pazienti.<\/p>

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Tahsin Ozatli

  • 4.2 Buono 19 recensioni
  • 2016 anni di esperienza
  • Turchia, Istanbul, Istinye University Liv Hospital Bahcesehir
  • Il medico è un oncologo specializzato nel trattamento dei tumori al seno, ai polmoni e gastrointestinali. Attualmente, il medico pratica presso l'Ospedale Universitario Istinye Liv.

    Con una carriera che si estende su molteplici istituzioni prestigiose, il medico ha servito come Specialista in Medicina Interna presso l'Ospedale Statale di Malatya, medico presso la Clinica Oncologica di Ankara e membro del Dipartimento di Oncologia presso l'Ospedale Regionale di Formazione e Ricerca di Erzurum.

    Il medico si è laureato presso la Facoltà di Medicina dell'Università di Selcuk e ha ottenuto il titolo di Professore Associato nel 2016.

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Cemil Bilir

  • 5 Eccellente 1 recensioni
  • 21 anni di esperienza
  • Turchia, Istanbul, VM Medical Park Pendik Hospital
  • Education & Expertise

    • 1998 to 2004 – Istanbul University, Istanbul Faculty of Medicine
    • 2005 to 2009 – Düzce University, Internal Medicine Specialization
    • 2009 to 2010 – Beytüşşebap State Hospital, Compulsory Internal Medicine Service
    • 2010 to 2013 – Bülent Ecevit University, Medical Oncology Specialization
    • 2013 to 2015 – Recep Tayyip Erdoğan University, Medical Oncology Compulsory Service
    • 2015 to Present – Associate Professor, Recep Tayyip Erdoğan University
    • 2015 to 2021 – Lecturer, Medical Oncology, Sakarya University Faculty of Medicine
    • 2020 to Present – Professor, Sakarya University Faculty of Medicine
    • 2020 to Present – Ph.D. Student, Inorganic Chemistry, Sakarya University

    Experience

    • 2008 – Cleveland Clinic, Rheumatology & Gastroenterology Rotation
    • 2016 to 2017 – Northeastern University, The Center for Pharmaceutical Biotechnology and Nanomedicine, Boston, U.S.

    Professional Memberships

    • TTOD (Turkish Society of Medical Oncology)
    • ASCO (American Society of Clinical Oncology)
    • ESMO (European Society for Medical Oncology)
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Baha Zengel

  • 12 anni di esperienza
  • Turchia, Smirne, Medicalpoint International Hospital
  • Dr. Baha Zengel is a general surgeon with expertise in breast, gallbladder, thyroid diseases, and hernia repairs. He graduated from Ege University Faculty of Medicine in 1990. In 2004, he earned a doctorate in Basic Oncology from Dokuz Eylül University. He became an Associate Professor of General Surgery in 2014 through the Inter-University Board.

    Dr. Zengel is skilled in advanced surgical procedures. His experience includes skin and breast-conserving mastectomy, oncoplastic breast surgery, laparoscopic cholecystectomy, sentinel lymph node biopsy, and ROLL/SNOLL techniques. He has held important positions at Izmir Bozyaka Training and Research Hospital, including Education Officer.

    He is a member of several professional associations. He serves on the Board of Directors of the Aegean Region Surgery Association and is a founding board member of the Basic Oncology Association.

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Mustafa Serkan Alemdar

  • Medico leader per Chemioterapia per carcinoma mammario
  • 4.5 Buono 6 recensioni
  • 20 anni di esperienza
  • Turchia, Adalia, Medical Park Antalya Hospital Complex
  • Education and Specialization

    • 2006: Kocaeli University Faculty of Medicine
    • 2014: Akdeniz University Faculty of Medicine, Internal Medicine
    • 2018: Akdeniz University Faculty of Medicine, Medical Oncology

    Experience

    • 2006 - 2008: Konya Derebucak District Hospital
    • 2009 - 2015: Akdeniz University Hospital
    • 2015: Antalya Kaş State Hospital
    • 2015 - 2016: İnönü University Faculty of Medicine
    • 2016 - 2021: Akdeniz University Hospital
    • 2021 - 2023: Antalya Training and Research Hospital
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Ercan Ozden

  • 5 Eccellente 1 recensioni
  • 27 anni di esperienza
  • Turchia, Istanbul, VM Medical Park Pendik Hospital
  • Dr. Ercan Ozden is a specialist in internal medicine and medical oncology. He earned his medical degree and completed his residency at Istanbul University, Cerrahpaşa Faculty of Medicine. He later received a subspecialty in medical oncology at Kocaeli University Faculty of Medicine from 2016 to 2020.

    Dr. Ozden has worked in medical oncology at Şırnak State Hospital. He has also served as an internal medicine specialist at Bağcılar Private Safa Hospital and Küçükçekmece Batı Bahat Hospital. He has extensive clinical experience in both internal medicine and oncology.

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Nail Paksoy

  • 4.5 Buono 2 recensioni
  • 15 anni di esperienza
  • accreditamenti:
  • Turchia, Istanbul, Medipol Bahçelievler Hospital

  • PROFESSIONAL EXPERIENCE

    2011-2012
    Erzurum Koprukoyu State Hospital
    Department: General Medicine

    2012-2017
    Istanbul University Cerrahpaşa Medical Faculty
    Department: Internal Medicine

    06/2017-10/2017
    Istanbul Gaziosmanpasa Taksim Training and Research Hospital
    Department: Internal Medicine

    10/2017-11/2018
    Istanbul University Istanbul Medical Faculty
    Department: Allergy and Immunology Fellowship

    2018/2022
    Istanbul University Oncology Institute
    Department: Medical Oncology Fellowship

    2022-2023
    Tekirdag City Hospital
    Department: Medical Oncology Specialist

    2023-present
    Istanbul Medipol University Medipol Bahcelievler Private Hospital
    Department: Medical Oncology Assoc. Prof.

     

    EDUCATION

    2005-2011
    Medical Education
    Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

    2012-2017
    Internal Medicine
    Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

    2017-2018
    Allergy-Immunology Fellowship
    Istanbul University Istanbul Medical Faculty
    Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

    2018-2022
    Medical Oncology Fellowship
    Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

    2022
    ESMO Board Certification in Medical Oncology
    10th September 2022 in Paris, France.

    2023
    Medical Oncology Assoc. Prof.
    Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

     

    INTERNATIONAL CLINICAL TRIALS:

    1. Astefania - ROCHE

    • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
    • Role: Subinvestigator

    2. PFİZER

    • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
    • Role: Subinvestigator

    3. RECITE - AMGEN

    • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
    • Role: Subinvestigator

    4. NAVIGATE - BAYER

    • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
    • Role: Subinvestigator

    5. RUBY - Tesaro (PRA)

    • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
    • Role: Subinvestigator

    6. ENGOT-ov43/GOG-3036 - MSD

    • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
    • Role: Subinvestigator

    7. ASTRA ZENECA

    • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
    • Role: Subinvestigator

    8. ROSY-O - ASTRA ZENECA

    • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
    • Role: Subinvestigator
    •  

    INTERNATIONAL PUBLICATIONS

    I. Published journal articles indexed by SCI, SSCI, and AHCI

    Weekly Paclitaxel in Classic Kaposi Sarcoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
    • Journal: Medicine, 102(5)

    Carboplatin Desensitization in Ovarian Carcinoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
    • Journal: Medicine, 101(45), e31726

    High-Dose Chemotherapy for Ewing’s Sarcoma

    • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
    • Journal: Medicine, 101(49), e32213

    Multidrug Refractory TFE3(+) Renal Cell Carcinoma

    • Authors: Paksoy, Nail, et al.
    • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

    Crizotinib Efficacy in NSCLC with MET Alterations

    • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
    • Journal: Medicine, 101(50), e32368

    Clinicopathological Features in ALK Mutant NSCLC

    • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
    • Journal: Medicine, 101(34)

    PSMA-Based Tumor Burden in Prostate Cancer

    • Authors: HAS SIMSEK, Duygu, et al.
    • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

    Atezolizumab in Metastatic Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: European Urology Focus, 2021, 7.5: 1061-1066

    Pulmonary Sarcomatoid Carcinoma

    • Authors: FERHATOGLU, Ferhat, et al.
    • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

    Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

    Atezolizumab with Chemotherapy in Small Cell Lung Cancer

    • Authors: GÜRBÜZ, Mustafa, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

    FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

    • Authors: AY, Seval, et al.
    • Journal: Journal of Chemotherapy, 2022, 1-7

    Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

    • Authors: CIL, Ibrahim, et al.
    • Journal: Tumori Journal, 2022, 108.1: 19-25

    Real-Life Efficacy of Osimertinib in Advanced NSCLC

    • Authors: HIZAL, Mutlu, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

    ALK-Positive Cells Percentage and Alectinib Efficacy

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
    • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

    Real-World Data on Alectinib in ALK-Positive NSCLC

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
    • Journal: Future Oncology, 18(23), 2573-2582

    Prognostic Factors in Metastatic RCC with T790M Mutation

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

    • Authors: DEMIR, Semra, et al.
    • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

    Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

    • Authors: ÖZDEMIR, Seçil Kepil, et al.
    • Journal: Allergy, 2019, 74.6: 1187-1190

    Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

    • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
    • Journal: The Oncologist, oyad257

    Subsequent Treatments in Hormone-Positive Breast Cancer Progression

    • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
    • Journal: BMC cancer, 23(1), 192

    Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
    • Journal: Scientific Reports, 13(1), 8779

    Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
    • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

    Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

    • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
    • Journal: European Journal of Breast Health, 19(2), 128

    Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

    • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
    • Journal: Future Oncology, 19(10), 727-736

    Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

    • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
    • Journal: [Not specified]

    Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

    • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
    • Journal: Medicine, 102(39), e35383

    Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

    • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
    • Journal: Medicine, 102(41), e35245

    Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

    Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

    Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

    Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

    Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

    Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

    Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

    Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

    Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

    Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

    Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

    Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

    Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

     

    Thesis:

    Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

    International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

    Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

    • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

    Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

    • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

    Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

    • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

    Efficacy of temozolomide in pretreated patients with metastatic sarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

    • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

    • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

    Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

    • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

    Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

    • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

    Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

    • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

     

     

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Eckhart Weidmann

  • 4.5 Buono 57 recensioni
  • 36 anni di esperienza
  • Germania, Francoforte sul Meno, Nordwest Clinic (Krankenhaus)
  • Il dottore è un esperto leader nel trattamento del linfoma non-Hodgkin e si specializza nel trattamento dei disturbi del sangue. Con oltre 30 anni di pratica, il dottore dirige il settore di Ematologia presso la Clinica Nordwest, concentrandosi su cure e ricerche ematologiche avanzate.<\/p>

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Irfan Cicin

  • 5 Eccellente 1 recensioni
  • 29 anni di esperienza
  • Turchia, Istanbul, İstinye University Liv Hospital Topkapı
  • Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

    Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

    Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Mariam Mohammed Hussein Abu Zeid

  • 17 anni di esperienza
  • Egitto, Il Cairo, Ospedali oncologici internazionali Shefaa Al Orman
  • Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

    She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

  • Mostra di più
Chemioterapia per carcinoma mammario
$150 - $250
Informazioni

Atakan Topcu

  • 5 Eccellente 3 recensioni
  • 13 anni di esperienza
  • Turchia, Istanbul, Medipol Acibadem District Hospital
  • Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

    He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

    Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Ayse Irem Yasin

  • 5 Eccellente 3 recensioni
  • 15 anni di esperienza
  • Turchia, Istanbul, Medipol Acibadem District Hospital
  • Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

    She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Liu Shi Xin

  • 40 anni di esperienza
  • Cina, Xiamen, Ospedale Xiamen Humanity
  • Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

    He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

    His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Tamar Jablonski-Perec

  • 4.2 Buono 13 recensioni
  • Israele, Gerusalemme, Hadassah Medical Center
  • La dottoressa è un'oncologa presso il Centro Medico Hadassah, avendo conseguito un Dottorato in Scienze Mediche presso l'Università Ebraica di Gerusalemme. Ha completato un tirocinio presso il prestigioso Centro Oncologico Sloan-Kettering di New York, migliorando la sua esperienza in oncologia.<\/p>

    Nel 1994, è diventata capo dell'Istituto di Oncologia e successivamente, nel 1998, ha guidato il Centro di Trattamento del Cancro al Seno. Entro il 2006, è stata nominata Professore del Dipartimento di Oncologia presso l'Università Ebraica. È attivamente coinvolta con diverse organizzazioni internazionali sul cancro ed è stata riconosciuta con una borsa di studio dalla Scuola Medica Hadassah.<\/p>

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Ofer Spielberg

  • 4.4 Buono 13 recensioni
  • Israele, Tel Aviv-Giaffa, Assuta Medical Center
  • Il medico è un oncoematologo esperto specializzato nel trattamento dei tumori del sangue e dei disturbi correlati. Con un focus su terapie innovative e cure personalizzate per i pazienti, il medico ha contribuito in modo significativo ai progressi nel campo. Il medico è affiliato a diverse istituzioni mediche di primo piano e ha pubblicato numerosi articoli di ricerca su riviste peer-reviewed.<\/p>

    Il medico è anche attivamente coinvolto in studi clinici che mirano a migliorare i risultati per i pazienti con malignità ematologiche. Certificato in ematologia e oncologia, il medico è riconosciuto per la sua esperienza sia nella pratica clinica che nella ricerca.<\/p>

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni